Three more life sciences companies priced their initial public offerings Sept. 25, signaling that public investors are still buying into the sector in a big way. Two of the three, high-profile cancer diagnostics company Foundation Medicine Inc. and late-stage eye therapeutics developer Ophthotech Corp., priced above their proposed ranges to raise more than $100 million apiece. Both also enjoyed strong first-day performances as well.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?